How Clinical Trials Work in Cancer Research (Phase 1 to 3)

Clinical trials are the machinery that turns a promising idea into an approved treatment, or proves that it should be abandoned. For patients and families, understanding how they work demystifies a process that can feel opaque and intimidating. This article explains the phases of cancer clinical trials in plain language, for education only. It is not medical advice and makes no treatment claims.

Why trials are structured in phases

A new therapy cannot be tested all at once, because the first and most important question is whether it is safe enough to study further. Clinical trials therefore proceed in phases, each answering a different question and each acting as a filter. The structure protects participants by limiting early exposure and protects the science by requiring evidence at each step before more people are enrolled. Every phase a therapy clears removes a layer of uncertainty, which is why later-stage results carry more weight than early ones.

Phase 1: is it safe, and at what dose

The first phase tests a therapy in a small group, often a few dozen people, to assess safety and to find an appropriate dose. The central questions are how the body handles the therapy, what side effects appear, and at what dose the risks become unacceptable. Phase 1 is not designed to prove that a therapy works, and any hint of benefit is preliminary. In oncology, Phase 1 trials often enroll patients for whom standard options have been exhausted, which is one reason informed consent about realistic expectations matters so much.

Phase 2: is there a signal of benefit

If a therapy clears Phase 1, it moves to a larger group, often a few dozen to a few hundred people, to look for a signal that it actually helps and to refine the dose. Phase 2 sharpens the question of efficacy while continuing to monitor safety. Many therapies fail here, when an approach that looked promising in early testing shows no meaningful effect. The historical data make this concrete: success rates fall sharply at each phase transition (Hay et al., 2014).

Phase 3: does it help, compared to the standard

The pivotal phase tests the therapy in a large group, often hundreds to thousands of people, usually by comparing it against the current standard of care. The strongest designs randomize participants between the new therapy and the comparison, which guards against bias and allows a fair measurement of benefit and harm. Phase 3 is expensive, slow, and decisive. A positive, well-designed Phase 3 trial is the evidence on which approval usually rests, and a negative one typically ends a program. The cumulative odds of traveling from first-in-human testing all the way to approval sit in the low double digits, and lower in oncology (Wong, Siah, and Lo, 2019).

Established Approved cancer treatments have passed this phased testing and regulatory review.

Still being tested A therapy in Phase 1 or 2 has not been shown to help, no matter how promising it appears.

Before and after: Phase 0 and Phase 4

Two bookends complete the picture. Some programs run a small exploratory Phase 0 study, using very low doses to learn how a therapy behaves in the body before fuller testing. After approval, Phase 4 studies continue to monitor a therapy in real-world use, tracking long-term safety and rarer side effects that smaller trials could not detect. Together these stages mean that evidence about a therapy keeps accumulating even after it reaches patients.

The protections built into every phase

Across all phases, certain protections are constant. An independent ethics board reviews and oversees the trial. Participants give informed consent that explains the risks and the unknowns. The trial follows a written protocol with predefined endpoints, and it is listed on a public registry so the work is transparent (ClinicalTrials.gov). These safeguards are what separate a real trial from an unproven offering, a distinction explored in experimental treatments, real vs hype.

Why the phases matter for reading the news

When a headline announces a cancer breakthrough, the single most useful fact is which phase produced it. An exciting Phase 1 result is a reason for further study, not a reason to expect a treatment. A positive Phase 3 result is far more meaningful. Knowing the phase lets a reader calibrate hope to evidence. The regulatory process these trials feed into is detailed in the founder's guide to the FDA approval process, and how this research is paid for is covered in how cancer research funding works.

What participation actually involves

Beyond the science of phases, it helps to understand what taking part in a trial means in practice. Participants are screened against detailed eligibility criteria, which exist to make the results interpretable and to protect people for whom the therapy might be unsafe. Those who enroll typically follow a more intensive schedule of visits, tests, and monitoring than standard care involves, which is part of how trials gather reliable data. Participation is voluntary at every stage, and a person can withdraw at any time without losing their right to other care. In many trials, participants may receive the standard of care plus the experimental element, or be assigned to a comparison group, which the informed consent explains clearly. None of this guarantees benefit, and that is the honest contract of a trial: a participant contributes to knowledge that may help future patients, and may or may not benefit personally. Understanding this trade honestly is part of distinguishing a legitimate trial from an unproven offering, a distinction developed in experimental treatments, real vs hype.